Type 2 17-β hydroxysteroid dehydrogenase: a novel target for osteoporosis treatment?
This review provides an up-to-date summary of the current status and recent progress in the production of 17-β HSD2 inhibitors as well as the future challenges in their clinical application.
Increasing the concentration of estradiol may be useful for the treatment of osteoporosis. Increasing of estradiol can be achieved by two essential strategies:1) by increasing its production or 2) inhibiting its degradation. As 17-β HSD2 is the main enzyme that catalyzes the degradation of esradiol in bone tissue, thus inhibiting this enzyme can increase estradiol concentration to help in treating osteoporosis especially in postmenopausal women. This review illustrates the most important inhibitors of 17-β HSD2 as well as the structure-activity relationship of these inhibitors. The in vivo studies and the adverse effects of some of these inhibitors are founds in this paper.